Krungsri Securities recommends buying shares of Bangkok Dusit Medical Services Public Company Limited, or BDMS, with a 2027 target price of 25 baht, and picks it as a top stock in the medical sector, citing its network of more than 50 hospitals, a diversified customer base, and a complete medical ecosystem. The research team expects net profit in the second half to grow compared with the same period last year and to recover from the first half of this year, driven by a recovery in Thai and foreign patients. Meanwhile, ROE is likely to rise from 14.8% in 2026 to 15.4% in 2028, and dividends are expected to increase from 0.75 baht per share in 2026 to 0.80 baht in 2028. For the third quarter of 2026, the research team preliminarily expects normal profit of 4,550 million baht, up 5% YoY and 43% QoQ, with medical revenue seen rising 8% YoY and 13% QoQ and the EBITDA margin recovering to 24.3% from 21.1% in the second quarter of 2026. Most recently, BDMS shares stood at 20.10 baht, up 0.30 baht, or 1.52%, with trading value of 1,114.27 million baht.
Bangkok Dusit Medical Services Public Company LimitedKrungsri Securities recommends buying BDMS with a 25 baht target price, citing expected H2 profit growth and rising ROE/dividends.
